Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LM-LLO-TT
- Development stage
- Unknown
- Lead developer
- Advaxis
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intraperitoneal
01
Overview
**LM-LLO-TT** is an investigational, attenuated *Listeria monocytogenes*-based cancer immunotherapy developed by Matter Bio. The engineered live bacterial vector delivers a tetanus-toxoid recall antigen into the tumor microenvironment, aiming to recruit and reactivate pre-existing tetanus-specific memory T-cell responses against tumor-containing tissue. Listeriolysin O supports intracellular bacterial-vector activity and antigen delivery. The lead program is being advanced for metastatic pancreatic ductal adenocarcinoma, with additional preclinical and IND-enabling programs in refractory ovarian cancer and glioblastoma.
- Other names
- Listeria monocytogenes 11-T856-1313 tetanus toxoidListeria-TTLm-LLO-TT
02
Targets
Tetanus toxoid-specific memory T cell
Beyond the preview
Go deeper on LM-LLO-TT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LM-LLO-TT.